Effects of single and repeated administration of 1,2,3,4-tetrahydroisoquinoline analogs on the binding of [11C]raclopride to dopamine D2 receptors in the mouse brain

Journal of Neural Transmission

Volumn 108, Issue 10, 2001, Pages 1111-1125

  Ishiwata, K ^a   Koyanagi, Y ^a   Saitoh, T ^b   Taguchi, K ^b   Toda, J ^b   Sano, T ^b   Senda, M ^a  

^a TOKYO METROPOLITAN INSTITUTE OF GERONTOLOGY   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

1,2,3,4 tetrahydroisoquinoline; Dopamine release; Parkinson's disease; Raclopride

Indexed keywords

1 BENZYL 1,2,3,4 TETRAHYDROISOQUINOLINE; 1 METHYL 1,2,3,4 TETRAHYDROISOQUINOLINE; 1,2 DIMETHYL 1,2,3,4 TETRAHYDROISOQUINOLINE; 1,2,3,4 TETRAHYDRO 2 METHYLISOQUINOLINE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 METHYLSPIPERONE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; DOPAMINE; DOPAMINE 2 RECEPTOR; EMONAPRIDE; HALOPERIDOL; RACLOPRIDE; TETRAHYDROISOQUINOLINE; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; VANOXERINE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DOSE RESPONSE; DRUG EFFECT; DRUG UPTAKE; LIGAND BINDING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RECEPTOR AFFINITY; RECEPTOR BINDING; STRIATE CORTEX;

ANIMALS; BRAIN; CARBON RADIOISOTOPES; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; ISOQUINOLINES; MALE; MICE; NEUROTOXINS; RACLOPRIDE; RECEPTORS, DOPAMINE D2; TETRAHYDROISOQUINOLINES;

EID: 0034750416     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020170001     Document Type: Article

References (36)

1. Biological and pathological study of endogenous 1-benzyl-1,2,3,4-tetrahydroisoquinoline-induced parkinsonism in the mouse
2. +
3. Beta-carboline analogs N-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP); endogenous factors underlying idiopathic parkinsonism?
4. 11C-raclopride is altered by drugs that modify synaptic dopamine levels
5. Dopamine-derived alkaloids in alcoholism and in Parkinson's disease and Huntington's disease
6. Saliylate protects against MPTP-induced impairments in dopaminergic neurotransmission at the striatal and nigral level in mice
7. Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
8. Amphetamine effects on dopamine release and synthesis rate studied in the rhesus monkey brain by positron emission tomography
9. 11C]semotiadil, a benzothiazine calcium antagonist
10. 11C]nemonapride in the mouse and rat brain
11. Novel endogenous 1,2,3,4-tetrahydroisoquinoline derivatives: Uptake by dopamine transporter and activity to induce parkinsonism
12. 11C]β-CIT from N-desmethyl precursor on a semi-preparative reversed phase ODS column
13. Tetrahydroisoquinoline and 1-methyltetrahydroisoquinoline are present as novel endogenous amines in rat brain
14. 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as parkinsonism-inducing agent: A novel endogenous amine in mouse brain and parkinsonian CSF
15. Chronic administration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate
16. Neurotoxins, parkinsonism and Parkinson's disease
17. Effect of acute and chronic administration of 1,2,3,4-tetrahydroisoquinoline on muscle tone, metabolism of dopamine in the striatum and tyrosine hydroxylase immunocytochemistry in the substantia nigra, in rats
18. Confirmation of the enantiomers of 1-methyl-1,2,3,4-tetrahydroisoquinoline in the mouse brain and foods applying gas chromatography/mass spectrometry with negative ion chemical ionization
19. N-methylation of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines, (R)-salsolinol, in rat brains: In vivo microdialysis study
20. Selective release of serotonin by endogenous alkaloids, 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines, (R)- and (S)-salsolinol, in the rat striatum; in vivo microdialysis study
21. Dopamine release within forebrain sites perfused with tetrahydroisoquinolines or tryptoline in the rat
22. Isoquinoline neurotoxins in the brain and Parkinson's disease
23. An endogenous substance of the brain, tetrahydroisoquinoline, produces parkinsonism in primates with decreased dopamine, tyrosine hydroxylase and biopterin in the nigrostriatal regions
24. 11C]β-CFT
25. N-methylated tetrahydroisoquinolines as dopaminergic neurotoxins
26. Presence of tetrahydroisoquinoline and 2-methyl-tetrahydroquinoline in Parkinsonian and normal human brains
27. The effect of 1,2,3,4-tetrahydroisoquinoline (TIQ) on mesencephalic dopaminergic neurons in C57BL/6J mice: Immunohistochemical studies-tyrosine hydroxylase
28. Tetrahydroisoquinoline and 1-methyltetrahydroisoquinoline are present in the human brain: Relation to Parkinson's disease
29. Tetrahydropapaveroline and its derivatives inhibit dopamine uptake through dopamine transporter expressed in HEK293 cells
30. +
31. 3H raclopride: Implications for positron emission tomography of the human brain
32. A highly efficient synthesis of 1-methyl, 1-benzyl, and 1-phenyl-1,2,3,4-tetrahydroisoquinolines by modified Pummerer reaction
33. Determination of ring conformation in 1-benzyl-1,2,3,4-tetrahydroisoquinolines and a new synthesis of the chiral compounds
34. 11C]methylspiperone with high specific activity and high radiochemical purity for PET studies: Suppression of its radiolysis
35. 1-Methyl-1,2,3,4-tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse, prevents parkinsonism-like behavior abnormalities
36. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds